Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis

Cell Metabolism

Volumn 25, Issue 1, 2017, Pages 152-165

  Mulvihill, Erin E ^a   Varin, Elodie M ^a   Gladanac, Bojana ^a   Campbell, Jonathan E ^a   Ussher, John R ^a   Baggio, Laurie L ^a   Yusta, Bernardo ^a   Ayala, Jennifer ^c   Burmeister, Melissa A ^c   Matthews, Dianne ^a   Bang, K W Annie ^a,b,d   Ayala, Julio E ^c   Drucker, Daniel J ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

dipeptidyl peptidase 4; endothelial cells; enterocytes; glucagon; glucagon like peptide 1; glucose metabolism; glucose dependent insulinotropic polypeptide; gut; hematopoietic cells; incretin; insulin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; SITAGLIPTIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HORMONE ACTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTESTINE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANIMAL; BIOLOGICAL MODEL; BLOOD; BONE MARROW TRANSPLANTATION; DRUG EFFECTS; ENTERIC FEEDING; ENZYMOLOGY; FEEDING BEHAVIOR; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INTESTINE; INTESTINE MUCOSA; LIPID DIET; MALE; METABOLISM;

ANIMALS; BONE MARROW TRANSPLANTATION; DIET, HIGH-FAT; DIPEPTIDYL PEPTIDASE 4; ENTERAL NUTRITION; FEEDING BEHAVIOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INCRETINS; INSULIN RESISTANCE; INTESTINAL MUCOSA; INTESTINES; MALE; MICE; MODELS, BIOLOGICAL; SITAGLIPTIN PHOSPHATE;

EID: 85006284676     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.10.007     Document Type: Article

References (37)

1. Ayala, J.E., Bracy, D.P., Hansotia, T., Flock, G., Seino, Y., Wasserman, D.H., Drucker, D.J., Insulin action in the double incretin receptor knockout mouse. Diabetes 57 (2008), 288–297.
2. Ayala, J.E., Bracy, D.P., James, F.D., Burmeister, M.A., Wasserman, D.H., Drucker, D.J., Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 151 (2010), 4678–4687.
3. Burcelin, R., Gourdy, P., Dalle, S., GLP-1-based strategies: a physiological analysis of differential mode of action. Physiology (Bethesda) 29 (2014), 108–121.
4. Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17 (2013), 819–837.
5. Conarello, S.L., Li, Z., Ronan, J., Roy, R.S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband, E., Moller, D.E., et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 100 (2003), 6825–6830.
6. de Lange, W.J., Halabi, C.M., Beyer, A.M., Sigmund, C.D., Germ line activation of the Tie2 and SMMHC promoters causes noncell-specific deletion of floxed alleles. Physiol. Genomics 35 (2008), 1–4.
7. Deacon, C.F., Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 (2004), 2181–2189.
8. Deacon, C.F., Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 13 (2011), 7–18.
9. Deacon, C.F., Johnsen, A.H., Holst, J.J., Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80 (1995), 952–957.
10. Drucker, D.J., Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30 (2007), 1335–1343.
11. Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
12. Flock, G., Baggio, L.L., Longuet, C., Drucker, D.J., Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56 (2007), 3006–3013.
13. Flock, G., Holland, D., Seino, Y., Drucker, D.J., GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 152 (2011), 374–383.
14. Hansen, L., Deacon, C.F., Orskov, C., Holst, J.J., Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140 (1999), 5356–5363.
15. Hansotia, T., Baggio, L.L., Delmeire, D., Hinke, S.A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J.J., Schuit, F., Drucker, D.J., Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 (2004), 1326–1335.
16. Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., Drucker, D.J., Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J. Clin. Invest. 117 (2007), 143–152.
17. Hjøllund, K.R., Deacon, C.F., Holst, J.J., Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 54 (2011), 2206–2208.
18. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A.L., Tsapas, A., Wender, R., Matthews, D.R. American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35 (2012), 1364–1379.
19. Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D.M., Eckardt, K., Kaufman, J.M., Ryden, M., Müller, S., et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60 (2011), 1917–1925.
20. Lamont, B.J., Li, Y., Kwan, E., Brown, T.J., Gaisano, H., Drucker, D.J., Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J. Clin. Invest. 122 (2012), 388–402.
21. Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.M., Pierres, M., Nielsen, P.F., Ribel, U., Watanabe, T., Drucker, D.J., Wagtmann, N., Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 97 (2000), 6874–6879.
22. Mulvihill, E.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35 (2014), 992–1019.
23. Nagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., Tanaka, I., Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism 52 (2003), 81–86.
24. Nakajima, S., Hira, T., Hara, H., Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats. Br. J. Nutr. 113 (2015), 1477–1488.
25. Nauck, M.A., Meier, J.J., The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 4 (2016), 525–536.
26. Omar, B., Ahrén, B., Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes 63 (2014), 2196–2202.
27. Rolin, B., Deacon, C.F., Carr, R.D., Ahrén, B., The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. Eur. J. Pharmacol. 494 (2004), 283–288.
28. Sandoval, D.A., D'Alessio, D.A., Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 95 (2015), 513–548.
29. Sauvé, M., Ban, K., Momen, M.A., Zhou, Y.-Q., Henkelman, R.M., Husain, M., Drucker, D.J., Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59 (2010), 1063–1073.
30. Smith, E.P., An, Z., Wagner, C., Lewis, A.G., Cohen, E.B., Li, B., Mahbod, P., Sandoval, D., Perez-Tilve, D., Tamarina, N., et al. The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 19 (2014), 1050–1057.
31. Tang, Y., Harrington, A., Yang, X., Friesel, R.E., Liaw, L., The contribution of the Tie2+ lineage to primitive and definitive hematopoietic cells. Genesis 48 (2010), 563–567.
32. Tatarkiewicz, K., Sablan, E.J., Polizzi, C.J., Villescaz, C., Parkes, D.G., Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor. Am. J. Physiol. Regul. Integr. Comp. Physiol. 306 (2014), R490–R498.
33. Utzschneider, K.M., Tong, J., Montgomery, B., Udayasankar, J., Gerchman, F., Marcovina, S.M., Watson, C.E., Ligueros-Saylan, M.A., Foley, J.E., Holst, J.J., et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31 (2008), 108–113.
34. Waget, A., Cabou, C., Masseboeuf, M., Cattan, P., Armanet, M., Karaca, M., Castel, J., Garret, C., Payros, G., Maida, A., et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152 (2011), 3018–3029.
35. Wang, Z., Grigo, C., Steinbeck, J., von Hörsten, S., Amann, K., Daniel, C., Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides 57 (2014), 109–117.
36. Yang, F., Zheng, T., Gao, Y., Baskota, A., Chen, T., Ran, X., Tian, H., Increased plasma DPP4 activity is an independent predictor of the onset of metabolic syndrome in Chinese over 4 years: result from the China National Diabetes and Metabolic Disorders Study. PLoS ONE, 9, 2014, e92222.
37. Yusta, B., Baggio, L.L., Koehler, J., Holland, D., Cao, X., Pinnell, L.J., Johnson-Henry, K.C., Yeung, W., Surette, M.G., Bang, K.W., et al. GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R. Diabetes 64 (2015), 2537–2549.